



The development and evolution of final containers for cell and gene therapies

Considerations for final containers






These considerations shape the design of the final container for cell and gene therapies







Low barrier to entry

Closed system

Safe for cryogenic

temperatures

Low barrier to entry

Screw-cap vials

Closed

Closed vials

Volume constraints

greater than 50 mL

Unsuitable for

industrial upscaling

Not hermetically sealed

Questionable

GMP-compliance

Require dedicated filling equipment

Allow for larger volumes

Legacy product from the blood industry

Well understood

Appropriate for low throughput through to full-scale automation

Closed-system solution

Specifically designed for

cell and gene therapies

Rigid container resistant to fracture

Volume range that meets current criteria for

approved therapies

CellSealTM CryoCase Appropriate for low throughput through to large-scale manufacturing

As the field of cell and gene therapies expands, different design principles for final



CellSeal™ Cryovials

Susceptible to fracture

Potentially high

particulate generation

Challenges with

high throughput

and automation

Limited to small volumes

New to the industry

therapy-specific final containers. CellSeal™ CryoCase

Specificity

containers are being developed.

These are departing from common designs in favor of increasingly cell and gene

CellSeal™ Cryovials

Cryo Bags

Closed vials

Screw-cap vials

Cryogenic straws

SextonBiotechnologies

Part of Biolife Solutions

RegMedNet | | focus